文档介绍：胆管癌最新化疗方案
Background: There is no known effective chemotherapy regimen for patients with unresectable/metastatic cholangiocarcinoma. We are here to report a single institution, retrospective chart review on using bination of irinotecan, capecitabine, and celecoxib in treating these patients.
Methods: From 9/03 to 11/04, 8 chemotherapy naive patients with a tissue diagnosis of unresectable/ cholangiocarcinoma were seen and treated with a regimen consisting of irinotecan 120mg/m2 on D1, capecitabine 1500mg/m2 D1-14 and celecoxib 200mg bid daily, Q21 days.
Results: Six females and two males, age 56-63 (median age=60), performance status(PS) between 0-2. A total of 64 treatments were given. Baseline CA 19-9 ranged from - 6068 u/ml (normal < 33). 7 patients evaluable for CA19-9 response and treatment toxicity. A decline in CA19-9 was seen in 100% (5/7 > 80% decline). CT scan: 2/7 had stable disease and 2/7 had a minimum response (<20% decrease in target tumor size). Toxicity: diarrhea: 5/7 grade 0, 2/7 grade 1; hand-foot syndrome: 6/7 grade 0, 1/7 grade 1; anemia: 1/7 grade 0, 4/7 grade 1, 2/7 grade 2; neutropenia: 4/7 grade 0, 1/7 grade 1, 2/7 grade 2. No other grade III/IV non-hematological toxicity. All patients were alive as of 12/09/04 (1 - 15 months from initiation of treatment). Two patients remain working full time. Median response duration and median sur